AGR2 and ovarian carcinoma: These findings suggest that AGR2 could serve as a good prognostic factor of HSP90 inhibition, which is in agreement with a recent report where tumor aggressiveness and poorer disease-free survival were related to the downregulation of AGR2, p21 and cyclin D1 in the presence of mutated p53 in ovarian carcinoma [104].